losartan has been researched along with Hypertension, Essential in 19 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
| Excerpt | Relevance | Reference |
|---|---|---|
| "We aimed to determine the efficacy and tolerability of a fixed-dose SPC consisting of 5 mg amlodipine, 100 mg losartan, 20 mg rosuvastatin, and 10 mg ezetimibe (A/L/R/E) in patients with concomitant hypertension and dyslipidemia." | 9.69 | A Randomized, Multicenter, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Quadruple Combination of Amlodipine, Losartan, Rosuvastatin, and Ezetimibe in Patients with Concomitant Essential Hypertension and Dyslipidemia. ( Ahn, Y; Chae, IH; Hong, SJ; Hong, TJ; Kang, DH; Kim, BK; Kim, H; Kim, HS; Kim, MC; Kim, MH; Kim, SH; Kim, SY; Kim, W; Rhee, MY, 2023) |
| "In this multicenter, randomized, double-blind, noninferiority trial in China, patients 18 to 65 years of age with mild essential hypertension were randomly allocated to receive either SXC or losartan for 8 weeks." | 9.51 | Efficacy and Safety of Chinese Herbal Medicine Compared With Losartan for Mild Essential Hypertension: A Randomized, Multicenter, Double-Blind, Noninferiority Trial. ( Cao, R; Chen, Y; Ding, R; Dong, G; Dong, Z; Du, J; Fan, J; Gao, Y; Hua, Q; Jiang, W; Lai, X; Li, Z; Mao, J; Wang, X; Wu, S; Wu, W; Wu, Z; Xiong, S; Xu, Y; Yuan, H; Zhang, G; Zhang, J; Zhen, H; Zhou, X, 2022) |
| "The objective of this study was to evaluate the efficacy and tolerability of a triple combination of amlodipine/losartan/rosuvastatin in patients with hypertension and hypercholesterolemia." | 9.24 | A Randomized, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and the Tolerability of a Triple Combination of Amlodipine/Losartan/Rosuvastatin in Patients With Comorbid Essential Hypertension and Hyperlipidemia. ( Cha, DH; Choi, JH; Choi, JY; Choi, KJ; Choi, SW; Hong, TJ; Jung, HO; Kim, KH; Kim, SM; Kim, SY; Kim, WS; Lee, HY; Lee, KJ; Oh, JH; Park, DG; Park, SW; Park, TH; Rha, SW; Rhee, MY; Ryu, DR; Shim, J; Song, PS; Yoo, BS, 2017) |
| "The objective of this study was to observe the antihypertensive effect of losartan and levamlodipine besylate on insulin resistance in patients with essential hypertension (EH) combined with isolated impaired fasting glucose (i-IFG)." | 9.22 | Effects of antihypertensive drugs losartan and levamlodipine besylate on insulin resistance in patients with essential hypertension combined with isolated impaired fasting glucose. ( Jiang, XS; Liu, L; Ning, N; Tan, MH; Wei, P; Xiao, WY; Yi, D; Zhou, L, 2016) |
| "Japanese patients with uncontrolled essential hypertension received single-blind losartan 50 mg/hydrochlorothiazide 12." | 9.20 | Efficacy and safety of fixed-dose losartan/hydrochlorothiazide/amlodipine combination versus losartan/hydrochlorothiazide combination in Japanese patients with essential hypertension. ( Azuma, K; Fujita, KP; Nishida, C; Numaguchi, H; Rakugi, H; Shimada, K; Shirakawa, M; Tsuchihashi, T; Yamaguchi, H, 2015) |
| "5)/amlodipine 5 mg (A5) versus co-administration of L50 plus A5 (L50+A5) in Japanese subjects with uncontrolled essential hypertension." | 9.20 | Add-on effect of hydrochlorothiazide 12.5 mg in Japanese subjects with essential hypertension uncontrolled with losartan 50 mg and amlodipine 5 mg. ( Azuma, K; Fujita, KP; Nishida, C; Numaguchi, H; Rakugi, H; Shimada, K; Shirakawa, M; Tsuchihashi, T; Yamaguchi, H, 2015) |
| " Angiotensin II type 1 receptor blocker losartan is potentially useful in controlling the central blood pressure and arterial stiffness in mild to moderate essential hypertension, while the effects of losartan in aged patients with essential hypertension are not entirely investigated." | 7.91 | Administration of losartan improves aortic arterial stiffness and reduces the occurrence of acute coronary syndrome in aged patients with essential hypertension. ( Fei, JC; Guo, T; Li, MM; Lv, YH; Miao, Z; Ou, WS; Wang, BX; Wang, SX; Zhang, ZM, 2019) |
| " Drug-related adverse events with an incidence ⩾ 2% in the L100/H12." | 6.79 | Efficacy and safety of losartan 100 mg/hydrochlorothiazide 12.5 mg in Japanese subjects with essential hypertension: two randomized, controlled trials. ( Azuma, K; Fujimoto, G; Fujita, KP; Hanson, ME; Nishida, C; Numaguchi, H; Rakugi, H; Shimada, K; Shirakawa, M; Tsuchihashi, T; Yamaguchi, H, 2014) |
| "We aimed to determine the efficacy and tolerability of a fixed-dose SPC consisting of 5 mg amlodipine, 100 mg losartan, 20 mg rosuvastatin, and 10 mg ezetimibe (A/L/R/E) in patients with concomitant hypertension and dyslipidemia." | 5.69 | A Randomized, Multicenter, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Quadruple Combination of Amlodipine, Losartan, Rosuvastatin, and Ezetimibe in Patients with Concomitant Essential Hypertension and Dyslipidemia. ( Ahn, Y; Chae, IH; Hong, SJ; Hong, TJ; Kang, DH; Kim, BK; Kim, H; Kim, HS; Kim, MC; Kim, MH; Kim, SH; Kim, SY; Kim, W; Rhee, MY, 2023) |
| "In this multicenter, randomized, double-blind, noninferiority trial in China, patients 18 to 65 years of age with mild essential hypertension were randomly allocated to receive either SXC or losartan for 8 weeks." | 5.51 | Efficacy and Safety of Chinese Herbal Medicine Compared With Losartan for Mild Essential Hypertension: A Randomized, Multicenter, Double-Blind, Noninferiority Trial. ( Cao, R; Chen, Y; Ding, R; Dong, G; Dong, Z; Du, J; Fan, J; Gao, Y; Hua, Q; Jiang, W; Lai, X; Li, Z; Mao, J; Wang, X; Wu, S; Wu, W; Wu, Z; Xiong, S; Xu, Y; Yuan, H; Zhang, G; Zhang, J; Zhen, H; Zhou, X, 2022) |
| "The objective of this study was to evaluate the efficacy and tolerability of a triple combination of amlodipine/losartan/rosuvastatin in patients with hypertension and hypercholesterolemia." | 5.24 | A Randomized, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and the Tolerability of a Triple Combination of Amlodipine/Losartan/Rosuvastatin in Patients With Comorbid Essential Hypertension and Hyperlipidemia. ( Cha, DH; Choi, JH; Choi, JY; Choi, KJ; Choi, SW; Hong, TJ; Jung, HO; Kim, KH; Kim, SM; Kim, SY; Kim, WS; Lee, HY; Lee, KJ; Oh, JH; Park, DG; Park, SW; Park, TH; Rha, SW; Rhee, MY; Ryu, DR; Shim, J; Song, PS; Yoo, BS, 2017) |
| "The objective of this study was to observe the antihypertensive effect of losartan and levamlodipine besylate on insulin resistance in patients with essential hypertension (EH) combined with isolated impaired fasting glucose (i-IFG)." | 5.22 | Effects of antihypertensive drugs losartan and levamlodipine besylate on insulin resistance in patients with essential hypertension combined with isolated impaired fasting glucose. ( Jiang, XS; Liu, L; Ning, N; Tan, MH; Wei, P; Xiao, WY; Yi, D; Zhou, L, 2016) |
| "Japanese patients with uncontrolled essential hypertension received single-blind losartan 50 mg/hydrochlorothiazide 12." | 5.20 | Efficacy and safety of fixed-dose losartan/hydrochlorothiazide/amlodipine combination versus losartan/hydrochlorothiazide combination in Japanese patients with essential hypertension. ( Azuma, K; Fujita, KP; Nishida, C; Numaguchi, H; Rakugi, H; Shimada, K; Shirakawa, M; Tsuchihashi, T; Yamaguchi, H, 2015) |
| " The Genetics of Drug Responsiveness in Essential Hypertension (GENRES) study is a double-blind, placebo-controlled cross-over study where each subject received amlodipine, bisoprolol,hydrochlorothiazide, and losartan, each as a monotherapy, in a randomized order." | 5.20 | Pharmacogenomics of hypertension: a genome‐wide, placebo‐controlled cross‐over study, using four classes of antihypertensive drugs. ( Boerwinkle, E; Chapman, AB; Cooper-DeHoff, RM; Donner, KM; Frau, F; Glorioso, N; Glorioso, V; Gong, Y; Gums, JG; Hiltunen, TP; Johnson, JA; Kontula, KK; Ripatti, S; Saarela, J; Salvi, E; Sarin, AP; Turner, ST; Zaninello, R, 2015) |
| "This exploratory study reports two plausible loci associated with SBP response to hydrochlorothiazide: TET2, an aldosterone-responsive mediator of αENaC gene transcription; and CSMD1, previously described as associated with hypertension in a case-control study." | 5.20 | TET2 and CSMD1 genes affect SBP response to hydrochlorothiazide in never-treated essential hypertensives. ( Argiolas, G; Barlassina, C; Boerwinkle, E; Braga, D; Carpini, SD; Chapman, AB; Chittani, M; Citterio, L; Condorelli, G; Cooper-Dehoff, RM; Cusi, D; Dominiczak, AF; Donner, KM; Frau, F; Fresu, G; Glorioso, N; Glorioso, V; Gong, Y; Hiltunen, TP; Johnson, JA; Kontula, KK; Lanzani, C; Manunta, P; Melander, O; Ortu, MF; Padmanabhan, S; Piras, DA; Pozzoli, S; Rivera, NV; Salvi, E; Simonini, M; Trimarco, B; Troffa, C; Turner, ST; Velayutham, D; Zaninello, R, 2015) |
| "5)/amlodipine 5 mg (A5) versus co-administration of L50 plus A5 (L50+A5) in Japanese subjects with uncontrolled essential hypertension." | 5.20 | Add-on effect of hydrochlorothiazide 12.5 mg in Japanese subjects with essential hypertension uncontrolled with losartan 50 mg and amlodipine 5 mg. ( Azuma, K; Fujita, KP; Nishida, C; Numaguchi, H; Rakugi, H; Shimada, K; Shirakawa, M; Tsuchihashi, T; Yamaguchi, H, 2015) |
| "These data suggest that lisinopril/lisinopril + hydrochlorothiazide, losartan/losartan + hydrochlorothiazide and valsartan/valsartan + hydrochlorothiazide alone or in combination with amlodipine are equally effective and well tolerated for the reduction of both systolic and diastolic blood pressure and improve arterial stiffness in patients with essential hypertension." | 3.91 | Effects of Different Antihypertensive Drug Combinations on Blood Pressure and Arterial Stiffness. ( Hebibovic, S; Jatic, Z; Rustempasic, E; Skopljak, A; Sukalo, A; Valjevac, A, 2019) |
| " Angiotensin II type 1 receptor blocker losartan is potentially useful in controlling the central blood pressure and arterial stiffness in mild to moderate essential hypertension, while the effects of losartan in aged patients with essential hypertension are not entirely investigated." | 3.91 | Administration of losartan improves aortic arterial stiffness and reduces the occurrence of acute coronary syndrome in aged patients with essential hypertension. ( Fei, JC; Guo, T; Li, MM; Lv, YH; Miao, Z; Ou, WS; Wang, BX; Wang, SX; Zhang, ZM, 2019) |
| "Adult patients with angiotensin receptor blocker (ARB)-resistant essential hypertension (n = 104) were enrolled and switched to combination therapy with losartan (50 mg/day) and hydrochlorothiazide (12." | 3.79 | Release from glomerular overload by the addition of low-dose thiazide in patients with angiotensin receptor blocker-resistant hypertension. ( Asakura, J; Hasegawa, H; Iwashita, T; Kawashima, K; Matsuda, A; Mitarai, T; Nakamura, T; Ogawa, T; Shimizu, T; Takayanagi, K; Tayama, Y, 2013) |
| "Reversal of left ventricular hypertrophy (LVH) in hypertensive patients appears to be a desirable goal to the reduction cardiac risk." | 2.84 | Effects of losartan on left ventricular mass: a three-year follow-up in elderly hypertensives with myocardial hypertrophy despite successful conventional antihypertensive treatment. ( Affricano, C; Bossini, A; Cassone, R; Gaudio, C; Lopreiato, F; Moroni, C; Scrofani, AR; Tolone, S, 2017) |
| " Drug-related adverse events with an incidence ⩾ 2% in the L100/H12." | 2.79 | Efficacy and safety of losartan 100 mg/hydrochlorothiazide 12.5 mg in Japanese subjects with essential hypertension: two randomized, controlled trials. ( Azuma, K; Fujimoto, G; Fujita, KP; Hanson, ME; Nishida, C; Numaguchi, H; Rakugi, H; Shimada, K; Shirakawa, M; Tsuchihashi, T; Yamaguchi, H, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 15 (78.95) | 24.3611 |
| 2020's | 4 (21.05) | 2.80 |
| Authors | Studies |
|---|---|
| Lai, X | 1 |
| Dong, Z | 1 |
| Wu, S | 1 |
| Zhou, X | 1 |
| Zhang, G | 1 |
| Xiong, S | 1 |
| Wu, W | 1 |
| Cao, R | 1 |
| Wang, X | 1 |
| Hua, Q | 1 |
| Du, J | 1 |
| Fan, J | 1 |
| Mao, J | 1 |
| Jiang, W | 1 |
| Yuan, H | 1 |
| Chen, Y | 1 |
| Xu, Y | 1 |
| Li, Z | 1 |
| Zhang, J | 1 |
| Dong, G | 1 |
| Zhen, H | 1 |
| Ding, R | 1 |
| Wu, Z | 1 |
| Gao, Y | 1 |
| Kim, MC | 1 |
| Ahn, Y | 1 |
| Kim, MH | 1 |
| Kim, SY | 2 |
| Hong, TJ | 2 |
| Rhee, MY | 2 |
| Kim, SH | 1 |
| Hong, SJ | 1 |
| Kim, H | 1 |
| Kim, W | 1 |
| Chae, IH | 1 |
| Kang, DH | 1 |
| Kim, BK | 1 |
| Kim, HS | 1 |
| Xie, M | 1 |
| Tang, T | 1 |
| Liang, H | 1 |
| Jatic, Z | 1 |
| Skopljak, A | 1 |
| Hebibovic, S | 1 |
| Sukalo, A | 1 |
| Rustempasic, E | 1 |
| Valjevac, A | 1 |
| Lee, JW | 1 |
| Choi, E | 1 |
| Son, JW | 1 |
| Youn, YJ | 1 |
| Ahn, SG | 1 |
| Ahn, MS | 1 |
| Kim, JY | 1 |
| Lee, SH | 1 |
| Yoon, J | 1 |
| Ryu, DR | 2 |
| Park, SM | 1 |
| Hong, KS | 1 |
| Yoo, BS | 2 |
| Moroni, C | 1 |
| Tolone, S | 1 |
| Lopreiato, F | 1 |
| Scrofani, AR | 1 |
| Bossini, A | 1 |
| Affricano, C | 1 |
| Cassone, R | 1 |
| Gaudio, C | 1 |
| Lee, HY | 1 |
| Choi, KJ | 1 |
| Cha, DH | 1 |
| Jung, HO | 1 |
| Choi, JH | 1 |
| Lee, KJ | 1 |
| Park, TH | 1 |
| Oh, JH | 1 |
| Kim, SM | 1 |
| Choi, JY | 1 |
| Kim, KH | 2 |
| Shim, J | 1 |
| Kim, WS | 1 |
| Choi, SW | 1 |
| Park, DG | 1 |
| Song, PS | 1 |
| Rha, SW | 1 |
| Park, SW | 1 |
| Zhang, ZM | 1 |
| Wang, BX | 1 |
| Ou, WS | 1 |
| Lv, YH | 1 |
| Li, MM | 1 |
| Miao, Z | 1 |
| Wang, SX | 1 |
| Fei, JC | 1 |
| Guo, T | 1 |
| Ihm, SH | 1 |
| Jeon, HK | 1 |
| Chae, SC | 1 |
| Lim, DS | 1 |
| Kim, KS | 1 |
| Choi, DJ | 1 |
| Ha, JW | 1 |
| Kim, DS | 1 |
| Cho, MC | 1 |
| Baek, SH | 1 |
| Hasegawa, H | 1 |
| Tayama, Y | 1 |
| Takayanagi, K | 1 |
| Asakura, J | 1 |
| Nakamura, T | 1 |
| Kawashima, K | 1 |
| Shimizu, T | 1 |
| Iwashita, T | 1 |
| Ogawa, T | 1 |
| Matsuda, A | 1 |
| Mitarai, T | 1 |
| Stamatelopoulos, K | 1 |
| Bramos, D | 1 |
| Manios, E | 1 |
| Alexaki, E | 1 |
| Kaladaridou, A | 1 |
| Georgiopoulos, G | 1 |
| Koroboki, E | 1 |
| Kolyviras, A | 1 |
| Stellos, K | 1 |
| Zakopoulos, N | 1 |
| Toumanidis, S | 1 |
| Rakugi, H | 3 |
| Tsuchihashi, T | 3 |
| Shimada, K | 3 |
| Numaguchi, H | 3 |
| Nishida, C | 3 |
| Yamaguchi, H | 3 |
| Fujimoto, G | 1 |
| Azuma, K | 3 |
| Shirakawa, M | 3 |
| Hanson, ME | 1 |
| Fujita, KP | 3 |
| Hiltunen, TP | 2 |
| Donner, KM | 2 |
| Sarin, AP | 1 |
| Saarela, J | 1 |
| Ripatti, S | 1 |
| Chapman, AB | 2 |
| Gums, JG | 1 |
| Gong, Y | 2 |
| Cooper-DeHoff, RM | 2 |
| Frau, F | 2 |
| Glorioso, V | 2 |
| Zaninello, R | 2 |
| Salvi, E | 2 |
| Glorioso, N | 2 |
| Boerwinkle, E | 2 |
| Turner, ST | 2 |
| Johnson, JA | 2 |
| Kontula, KK | 2 |
| Chittani, M | 1 |
| Lanzani, C | 1 |
| Ortu, MF | 1 |
| Fresu, G | 1 |
| Citterio, L | 1 |
| Braga, D | 1 |
| Piras, DA | 1 |
| Carpini, SD | 1 |
| Velayutham, D | 1 |
| Simonini, M | 1 |
| Argiolas, G | 1 |
| Pozzoli, S | 1 |
| Troffa, C | 1 |
| Padmanabhan, S | 1 |
| Dominiczak, AF | 1 |
| Melander, O | 1 |
| Rivera, NV | 1 |
| Condorelli, G | 1 |
| Trimarco, B | 1 |
| Manunta, P | 1 |
| Cusi, D | 1 |
| Barlassina, C | 1 |
| Wang, J | 1 |
| Qiu, B | 1 |
| Du, JL | 1 |
| Deng, SB | 1 |
| Liu, YJ | 1 |
| She, Q | 1 |
| MacDonald, TM | 1 |
| Williams, B | 1 |
| Caulfield, M | 1 |
| Cruickshank, JK | 1 |
| McInnes, G | 1 |
| Sever, P | 1 |
| Webb, DJ | 1 |
| Mackenzie, IS | 1 |
| Salsbury, J | 1 |
| Morant, S | 1 |
| Ford, I | 1 |
| Brown, MJ | 1 |
| Xiao, WY | 1 |
| Ning, N | 1 |
| Tan, MH | 1 |
| Jiang, XS | 1 |
| Zhou, L | 1 |
| Liu, L | 1 |
| Yi, D | 1 |
| Wei, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of Co-administered HGP0904, HGP0608 and HGP0816 in Patients With Hypertension and Dyslipidemia: A Randomized, Double-blind, Multicenter, Phase 3 Study[NCT02899455] | Phase 3 | 146 participants (Actual) | Interventional | 2014-07-31 | Completed | ||
| A Phase III, Randomized, Active-comparator Controlled Clinical Trial to Study the Efficacy and Safety of MK-0954A in Japanese Patients With Essential Hypertension Uncontrolled With the High Dose of Losartan Potassium[NCT01307046] | Phase 3 | 336 participants (Actual) | Interventional | 2011-03-29 | Completed | ||
| A Phase III, Randomized, Active-comparator Controlled and a Long-term Clinical Trial to Study the Safety of MK-0954A (L100/H12.5 mg) in Japanese Patients With Essential Hypertension Uncontrolled With MK-954H (L50/H12.5 mg) [PREMINENT®][NCT01307033] | Phase 3 | 278 participants (Actual) | Interventional | 2011-03-29 | Completed | ||
| A Phase III, Randomized, Active-Comparator Controlled Clinical Trial to Study the Efficacy and Safety of MK-0954E in Japanese Patients With Essential Hypertension Uncontrolled With Losartan and Amlodipine Co-administration[NCT01302691] | Phase 3 | 327 participants (Actual) | Interventional | 2011-01-01 | Completed | ||
| A Phase III, Randomized, Active-Comparator Controlled Clinical Trial to Study the Efficacy and Safety of MK-0954E in Japanese Patients With Essential Hypertension Uncontrolled With MK-954H (L50/H12.5 mg) [PREMINENT®] and an Open-label, Long-term Clinical [NCT01299376] | Phase 3 | 286 participants (Actual) | Interventional | 2011-01-24 | Completed | ||
| A Randomised Double-blind Cross-over Single-centre Study on Molecular Genetics of Drug Responsiveness in Essential Hypertension[NCT03276598] | Phase 4 | 233 participants (Actual) | Interventional | 1999-11-25 | Completed | ||
| Increasing Stay-on-therapy in Hypertensive Patients Treated With First-line Diuretics: An Active Pharmacosurveillance and Pharmacogenetic Study.[NCT00408512] | Phase 4 | 2,500 participants (Anticipated) | Interventional | 2006-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Sitting diastolic blood pressure was measured by automated sphygmomanometer pre-dose on Day 1 (baseline) and at 24 ± 2 hours after the last study drug administration (Day 56 ± 7 days). (NCT01307046)
Timeframe: Baseline and Week 8
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| MK-0954A | -8.7 |
| Losartan | -3.6 |
Sitting systolic blood pressure was measured by automated sphygmomanometer pre-dose on Day 1 (baseline) and at 24 ± 2 hours after the last study drug administration (Day 56 ± 7 days). (NCT01307046)
Timeframe: Baseline and Week 8
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| MK-0954A | -14.5 |
| Losartan | -5.4 |
(NCT01307046)
Timeframe: 8 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| MK-0954A | 31.3 |
| Losartan | 26.5 |
Blood pressure (BP) was measured with an automatic sphygmomanometer after participant has been resting in a sitting position for at least 10 minutes. BP was determined averaging 3 replicate measurements obtained at least a 1- to 2-minute interval between BP measurements. The recorded BP was the calculated average of the 3 readings. (NCT01307033)
Timeframe: Baseline and Week 8 (End of Double-blind Period)
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| MK-0954H (L50/H12.5) | -5.3 |
| MK-0954A (L100/H12.5) | -5.0 |
Blood pressure (BP) was measured with an automatic sphygmomanometer after participant has been resting in a sitting position for at least 10 minutes. BP was determined averaging 3 replicate measurements obtained at least a 1- to 2-minute interval between BP measurements. The recorded BP was the calculated average of the 3 readings. (NCT01307033)
Timeframe: Baseline and Week 8 (End of Double-blind Period)
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| MK-0954H (L50/H12.5) | -6.2 |
| MK-0954A (L100/H12.5) | -8.5 |
(NCT01307033)
Timeframe: Up to 52 weeks
| Intervention | Percentage of Participants (Number) |
|---|---|
| L50/H12.5→L100/H12.5 Open Label (Period 2) | 71.0 |
| L100/H12.5→L100/H12.5 Open Label (Period 2) | 72.4 |
Sitting diastolic blood pressure was measured by automated sphygmomanometer pre-dose on Day 1 (baseline) and at 24 ± 2 hours after the last study drug administration at Week 8. The difference between the baseline and Week 8 assessments was calculated and summarized by treatment arm. (NCT01302691)
Timeframe: Baseline and Week 8
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| L50/H12.5/A5 | -9.1 |
| L50 + A5 | -8.0 |
Sitting systolic blood pressure was measured by automated sphygmomanometer pre-dose on Day 1 (baseline) and at 24 ± 2 hours after the last study drug administration at Week 8. The difference between the baseline and Week 8 assessments was calculated and summarized by treatment arm. (NCT01302691)
Timeframe: Baseline and Week 8
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| L50/H12.5/A5 | -13.4 |
| L50 + A5 | -10.2 |
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. The percentage of participants who experienced at least 1 AE during the 10-week treatment and follow-up period were summarized by study drug received. (NCT01302691)
Timeframe: up to 14 days after last dose of study drug (up to 10 weeks)
| Intervention | Percentage of Participants (Number) |
|---|---|
| L50/H12.5/A5 | 30.5 |
| L50 + A5 | 28.8 |
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. Percentage of participants that experienced at least 1 AE that was reported as possibly, probably, or definitely related to the study drug by the investigator during the 10-week treatment and follow-up period were summarized by study drug received. (NCT01302691)
Timeframe: up to 14 days after last dose of study drug (up to 10 weeks)
| Intervention | Percentage of Participants (Number) |
|---|---|
| L50/H12.5/A5 | 11.6 |
| L50 + A5 | 3.7 |
An SAE is any AE occurring at any dose or during any use of Sponsor's product that does the following: results in death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; is a cancer; is associated with an overdose; is another important medical event. Percentage of participants that experienced at least 1 SAE that was reported as possibly, probably, or definitely related to the study drug by the investigator during the 10-week treatment and follow-up period were summarized by study drug received (NCT01302691)
Timeframe: up to 14 days after last dose of study drug (up to 10 weeks)
| Intervention | Percentage of Participants (Number) |
|---|---|
| L50/H12.5/A5 | 0.0 |
| L50 + A5 | 0.0 |
An SAE is any AE occurring at any dose or during any use of Sponsor's product that does the following: results in death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; is a cancer; is associated with an overdose; is another important medical event. The percentage of participants who experienced at least 1 SAE during the 10-week treatment and follow-up period were summarized by study drug received. (NCT01302691)
Timeframe: up to 14 days after last dose of study drug (up to 10 weeks)
| Intervention | Percentage of Participants (Number) |
|---|---|
| L50/H12.5/A5 | 0.6 |
| L50 + A5 | 0.6 |
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. The percentage of participants who had study drug stopped during the 8-week treatment period due to an AE regardless of whether or not they completed the study was summarized by treatment arm (NCT01302691)
Timeframe: up to 8 weeks
| Intervention | Percentage of Participants (Number) |
|---|---|
| L50/H12.5/A5 | 1.2 |
| L50 + A5 | 0.0 |
Sitting diastolic blood pressure was measured by automated sphygmomanometer pre-dose on Day 1 (baseline) and at 24 ± 2 hours after the last study drug administration at Week 8. The difference between the baseline and Week 8 assessments was calculated and summarized by treatment arm. (NCT01299376)
Timeframe: Baseline and Week 8
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| L50/H12.5/A5 | -12.1 |
| L50/H12.5 | -6.2 |
Sitting systolic blood pressure was measured by automated sphygmomanometer pre-dose on Day 1 (baseline) and at 24 ± 2 hours after the last study drug administration at Week 8. (NCT01299376)
Timeframe: Baseline and Week 8
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| L50/H12.5/A5 | -17.7 |
| L50/H12.5 | -7.5 |
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. The percentage of participants who experienced at least 1 AE during the 8-week double-blind treatment period were summarized by study drug received. (NCT01299376)
Timeframe: up to Week 8
| Intervention | Percentage of Participants (Number) |
|---|---|
| L50/H12.5/A5 | 27.0 |
| L50/H12.5 | 29.7 |
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. The percentage of participants that experienced at least 1 AE during long-term period was summarized. (NCT01299376)
Timeframe: Week 9 up to Week 52 for L50/H12.5→L50/H12.5/A5 arm; Week 1 to Week 52 for L50/H12.5/A5→L50/H12.5/A5
| Intervention | Percentage of Participants (Number) |
|---|---|
| L50/H12.5/A5→L50/H12.5/A5 | 70.9 |
| L50/H12.5→L50/H12.5/A5 | 66.2 |
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. Percentage of participants that experienced at least 1 AE that was reported as possibly, probably, or definitely related to the study drug by the investigator during the 8-week double-blind treatment period were summarized by study drug received. (NCT01299376)
Timeframe: up to Week 8
| Intervention | Percentage of Participants (Number) |
|---|---|
| L50/H12.5/A5 | 12.1 |
| L50/H12.5 | 14.5 |
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. Percentage of participants that experienced at least 1 AE that was reported as possibly, probably, or definitely related to the study drug by the investigator during the long-term reporting period was summarized. (NCT01299376)
Timeframe: Week 9 up to Week 52 for L50/H12.5→L50/H12.5/A5 arm; Week 1 to Week 52 for L50/H12.5/A5→L50/H12.5/A5
| Intervention | Percentage of Participants (Number) |
|---|---|
| L50/H12.5/A5→L50/H12.5/A5 | 27.7 |
| L50/H12.5→L50/H12.5/A5 | 14.3 |
An SAE is any AE occurring at any dose or during any use of Sponsor's product that does the following: results in death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; is a cancer; is associated with an overdose; is another important medical event. the percentage of participants that experienced an SAE that assessed as possibly, probably, or definitely related to the study drug by the investigator was summarized. (NCT01299376)
Timeframe: Week 9 up to Week 52 for L50/H12.5→L50/H12.5/A5 arm; Week 1 to Week 52 for L50/H12.5/A5→L50/H12.5/A5
| Intervention | Percentage of Participants (Number) |
|---|---|
| L50/H12.5/A5→L50/H12.5/A5 | 0.0 |
| L50/H12.5→L50/H12.5/A5 | 0.8 |
An SAE is any AE occurring at any dose or during any use of Sponsor's product that does the following: results in death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; is a cancer; is associated with an overdose; is another important medical event. Percentage of participants that experienced at least 1 SAE that was reported as possibly, probably, or definitely related to the study drug by the investigator during the 8-week double-blind treatment period were summarized by study drug received. (NCT01299376)
Timeframe: up to Week 8
| Intervention | Percentage of Participants (Number) |
|---|---|
| L50/H12.5/A5 | 0.0 |
| L50/H12.5 | 0.0 |
An SAE is any AE occurring at any dose or during any use of Sponsor's product that does the following: results in death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; is a cancer; is associated with an overdose; is another important medical event. Those SAEs assessed as possibly, probably, or definitely related to the study drug during the long-term period were summarized. (NCT01299376)
Timeframe: Week 9 up to Week 52 for L50/H12.5→L50/H12.5/A5 arm; Week 1 to Week 52 for L50/H12.5/A5→L50/H12.5/A5
| Intervention | Percentage of Participants (Number) |
|---|---|
| L50/H12.5/A5→L50/H12.5/A5 | 2.1 |
| L50/H12.5→L50/H12.5/A5 | 3.0 |
An SAE is any AE occurring at any dose or during any use of Sponsor's product that does the following: results in death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; is a cancer; is associated with an overdose; is another important medical event. The percentage of participants who experienced at least 1 SAE during the 8-week double-blind treatment period were summarized by study drug received. (NCT01299376)
Timeframe: up to Week 8
| Intervention | Percentage of Participants (Number) |
|---|---|
| L50/H12.5/A5 | 0.7 |
| L50/H12.5 | 1.4 |
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. The percentage of participants who had study drug stopped during the 8-week double-blind treatment period due to an AE regardless of whether or not they completed the study was summarized by treatment arm. (NCT01299376)
Timeframe: up to Week 8
| Intervention | Percentage of Participants (Number) |
|---|---|
| L50/H12.5/A5 | 0.7 |
| L50/H12.5 | 1.4 |
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. The percentage of participants who had study drug discontinued during the 44 week extension due to an AE regardless of completion status were summarized. (NCT01299376)
Timeframe: Week 9 up to Week 52 for L50/H12.5→L50/H12.5/A5 arm; Week 1 to Week 52 for L50/H12.5/A5→L50/H12.5/A5
| Intervention | Percentage of Participants (Number) |
|---|---|
| L50/H12.5/A5→L50/H12.5/A5 | 2.1 |
| L50/H12.5→L50/H12.5/A5 | 2.3 |
1 review available for losartan and Hypertension, Essential
| Article | Year |
|---|---|
Efficacy of single-pill combination in uncontrolled essential hypertension: A systematic review and network meta-analysis.
Topics: Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihyperten | 2023 |
14 trials available for losartan and Hypertension, Essential
| Article | Year |
|---|---|
Efficacy and Safety of Chinese Herbal Medicine Compared With Losartan for Mild Essential Hypertension: A Randomized, Multicenter, Double-Blind, Noninferiority Trial.
Topics: Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drugs, Chinese Herbal; Essential Hyper | 2022 |
A Randomized, Multicenter, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Quadruple Combination of Amlodipine, Losartan, Rosuvastatin, and Ezetimibe in Patients with Concomitant Essential Hypertension and Dyslipidemia.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Cholesterol, LDL; Double-Blind Method; Dyslipid | 2023 |
Comparison of Blood Pressure Variability Between Losartan and Amlodipine in Essential Hypertension (COMPAS-BPV).
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Essenti | 2020 |
Effects of losartan on left ventricular mass: a three-year follow-up in elderly hypertensives with myocardial hypertrophy despite successful conventional antihypertensive treatment.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Essential Hypertension; Female; Follow-Up Studies; Hu | 2017 |
A Randomized, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and the Tolerability of a Triple Combination of Amlodipine/Losartan/Rosuvastatin in Patients With Comorbid Essential Hypertension and Hyperlipidemia.
Topics: Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Blood Pressure; Comorbidity; Do | 2017 |
Benidipine has effects similar to losartan on the central blood pressure and arterial stiffness in mild to moderate essential hypertension.
Topics: Adolescent; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Calcium Channel Bl | 2013 |
Efficacy and safety of losartan 100 mg/hydrochlorothiazide 12.5 mg in Japanese subjects with essential hypertension: two randomized, controlled trials.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; As | 2014 |
Efficacy and safety of losartan 100 mg/hydrochlorothiazide 12.5 mg in Japanese subjects with essential hypertension: two randomized, controlled trials.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; As | 2014 |
Efficacy and safety of losartan 100 mg/hydrochlorothiazide 12.5 mg in Japanese subjects with essential hypertension: two randomized, controlled trials.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; As | 2014 |
Efficacy and safety of losartan 100 mg/hydrochlorothiazide 12.5 mg in Japanese subjects with essential hypertension: two randomized, controlled trials.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; As | 2014 |
Efficacy and safety of fixed-dose losartan/hydrochlorothiazide/amlodipine combination versus losartan/hydrochlorothiazide combination in Japanese patients with essential hypertension.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Combinations; Drug Monitoring; Essen | 2015 |
Efficacy and safety of fixed-dose losartan/hydrochlorothiazide/amlodipine combination versus losartan/hydrochlorothiazide combination in Japanese patients with essential hypertension.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Combinations; Drug Monitoring; Essen | 2015 |
Efficacy and safety of fixed-dose losartan/hydrochlorothiazide/amlodipine combination versus losartan/hydrochlorothiazide combination in Japanese patients with essential hypertension.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Combinations; Drug Monitoring; Essen | 2015 |
Efficacy and safety of fixed-dose losartan/hydrochlorothiazide/amlodipine combination versus losartan/hydrochlorothiazide combination in Japanese patients with essential hypertension.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Combinations; Drug Monitoring; Essen | 2015 |
Pharmacogenomics of hypertension: a genome‐wide, placebo‐controlled cross‐over study, using four classes of antihypertensive drugs.
Topics: Adult; Aldehyde Oxidoreductases; Amlodipine; Antihypertensive Agents; Benzimidazoles; Biphenyl Compo | 2015 |
TET2 and CSMD1 genes affect SBP response to hydrochlorothiazide in never-treated essential hypertensives.
Topics: Adult; Aged; Aldosterone; Antihypertensive Agents; Blood Pressure; Case-Control Studies; Dioxygenase | 2015 |
Add-on effect of hydrochlorothiazide 12.5 mg in Japanese subjects with essential hypertension uncontrolled with losartan 50 mg and amlodipine 5 mg.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Blood Pressure; Double-Blind Me | 2015 |
The effects of a low-salt diet on the efficacy of different antihypertensive drug regimens.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Diet, Sodium-R | 2015 |
Monotherapy versus dual therapy for the initial treatment of hypertension (PATHWAY-1): a randomised double-blind controlled trial.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulat | 2015 |
Effects of antihypertensive drugs losartan and levamlodipine besylate on insulin resistance in patients with essential hypertension combined with isolated impaired fasting glucose.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Essential Hypertension; F | 2016 |
4 other studies available for losartan and Hypertension, Essential
| Article | Year |
|---|---|
Effects of Different Antihypertensive Drug Combinations on Blood Pressure and Arterial Stiffness.
Topics: Aged; Amlodipine; Antihypertensive Agents; Arteries; Blood Pressure; Diastole; Drug Combinations; Es | 2019 |
Administration of losartan improves aortic arterial stiffness and reduces the occurrence of acute coronary syndrome in aged patients with essential hypertension.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Antihypertensive Agents; China; Cross-Sectional St | 2019 |
Release from glomerular overload by the addition of low-dose thiazide in patients with angiotensin receptor blocker-resistant hypertension.
Topics: Aged; Aged, 80 and over; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Dose-Response Relatio | 2013 |
Pleiotropic effects of the acute and chronic inhibition of the renin-angiotensin system in hypertensives.
Topics: Acute Disease; Adult; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Case-Control S | 2014 |